J Hepatology: 青春期胆道闭锁成年后需肝移植的影响因素

2019-06-28 不详 MedSci原创

在胆道闭锁(BA)患者中,能够存活至成年的概率只有14%-44%,与门静脉高压症(PHT)和胆管炎相关的并发症在BA成年期最常见的并发症。本项研究的目的是确定可以预测年轻人是否会在年龄> 16岁时需要LT的影响因素。

背景与目的
在胆道闭锁(BA)患者中,能够存活至成年的概率只有14%-44%,与门静脉高压症(PHT)和胆管炎相关的并发症在BA成年期最常见的并发症。本项研究的目的是确定可以预测年轻人是否会在年龄> 16岁时需要LT的影响因素。

方法
本项研究收集了英国1980 - 1996年间接受Kasai门体造口术(KP)的397名患者进行了单中心回顾性分析研究。在KP之后,111/397(28%)患者存活到16岁。随访中,第1组为长期存活组年龄>67岁,第2组为需肝移植组:22岁时需要LT。并进行相关分析研究。

结果
在多变量分析中,16岁时对LT的需求与较高的总胆红素(风险比1.03,p= 0.019)和较低的肌酐(风险比0.95,p = 0.040)相关,16岁时总胆红素水平≥21μmol/ L(AUROC = 0.848)预测在> 16岁时需要LT,敏感性为85%,特异性为74%。青春期的胆管炎发作与> 16岁时需要LT的风险增加5倍相关。

结论
胆红素≥21μmol/ L,PHT或食管静脉曲张以及青春期胆管炎均是BA患者需LT的预测因素。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1275537, encodeId=be5512e553775, content=<a href='/topic/show?id=5d0299032b9' target=_blank style='color:#2F92EE;'>#青春期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99032, encryptionId=5d0299032b9, topicName=青春期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427330, encodeId=b3e3142e330b4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463971, encodeId=aed814639e166, content=<a href='/topic/show?id=c5af8355eea' target=_blank style='color:#2F92EE;'>#胆道闭锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83557, encryptionId=c5af8355eea, topicName=胆道闭锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47726553775, createdName=marlenexl, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465589, encodeId=005414655898d, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1275537, encodeId=be5512e553775, content=<a href='/topic/show?id=5d0299032b9' target=_blank style='color:#2F92EE;'>#青春期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99032, encryptionId=5d0299032b9, topicName=青春期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427330, encodeId=b3e3142e330b4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463971, encodeId=aed814639e166, content=<a href='/topic/show?id=c5af8355eea' target=_blank style='color:#2F92EE;'>#胆道闭锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83557, encryptionId=c5af8355eea, topicName=胆道闭锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47726553775, createdName=marlenexl, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465589, encodeId=005414655898d, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
    2019-06-30 gwc384
  3. [GetPortalCommentsPageByObjectIdResponse(id=1275537, encodeId=be5512e553775, content=<a href='/topic/show?id=5d0299032b9' target=_blank style='color:#2F92EE;'>#青春期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99032, encryptionId=5d0299032b9, topicName=青春期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427330, encodeId=b3e3142e330b4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463971, encodeId=aed814639e166, content=<a href='/topic/show?id=c5af8355eea' target=_blank style='color:#2F92EE;'>#胆道闭锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83557, encryptionId=c5af8355eea, topicName=胆道闭锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47726553775, createdName=marlenexl, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465589, encodeId=005414655898d, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1275537, encodeId=be5512e553775, content=<a href='/topic/show?id=5d0299032b9' target=_blank style='color:#2F92EE;'>#青春期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99032, encryptionId=5d0299032b9, topicName=青春期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427330, encodeId=b3e3142e330b4, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463971, encodeId=aed814639e166, content=<a href='/topic/show?id=c5af8355eea' target=_blank style='color:#2F92EE;'>#胆道闭锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83557, encryptionId=c5af8355eea, topicName=胆道闭锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47726553775, createdName=marlenexl, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465589, encodeId=005414655898d, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Sun Jun 30 12:42:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]

相关资讯

J Gastroenterology: 吉西他滨联合顺铂作为一线化疗的晚期胆道癌患者预后风险评估

吉西他滨联合顺铂(GC)治疗晚期胆道癌(BTC)患者被认为是标准的化疗方案,但是很少有研究报道其疗效如何。因此,本研究的目的是明确影响接受GC治疗的晚期BTC患者的总生存(OS)的因素。

GUT : 他汀类药物可以减少胆管癌的发生

他汀类药物作为一种个降血脂的药物其在其他方面也有很大的作用,有文献报道他汀类药物使用与胆道癌(BTC)风险之间存在联系,本文就此进行了相关研究。

Dig Liver Dis:生长抑素类似物治疗神经内分泌肿瘤患者引起胆道结石的原因分析

生长抑素类似物是神经内分泌肿瘤治疗的主要手段。胆结石疾病是生长抑素类似物的潜在严重不良事件,因此本项研究旨在评估用生长抑素类似物治疗神经内分泌肿瘤患者的胆道结石病发病率和相关因素。

J Gastroenterology:吉西他滨联合顺铂作为一线化疗的晚期胆道癌患者治疗结果的预测因子分析

吉西他滨加顺铂(GC)是作为晚期胆道癌(BTC)治疗的标准的化疗方案,但是很少有研究清楚地确定患者的预后因素。本研究的目的是确定接受GC治疗的晚期BTC患者的总生存(OS)的预测因素。

Gastroenterology:肝移植术后原发性胆汁性胆管炎复发的危险因素

临床工作中常常能发现原发性胆汁性胆管炎(PBC)经常在肝移植后复发。因此,本项研究就设计了一个多中心国际队列(全球PBC研究组),评估了与PBC复发相关的危险因素及其对患者和移植物存活的影响。

Gastroenterology Report: 术前胆道引流与胆管癌患者的存活时间缩短有关

尽管术前胆管引流(PBD)经常在胆管癌(CCA)患者中进行,但其对患者存活率的影响尚不清楚。本项研究的目的是评估PBD对肝外CCA患者总体生存的影响。